Effective November 5th, the following test order names will be modified. These changes have been made to enhance clarify regarding the testing performed. In all cases, prior Cerner names are set as aliases that direct to the new Epic order names.
On May 1, 2017, Spectrum Health Regional Laboratory adjusted the reference range for C-Reactive Protein (CRP) from ≤10 mg/L to ≤5.0 mg/L.
Anal cancer incidence, including in situ and invasive carcinoma is on the rise in North America, with a sharp increase over the past several decades. Oncogenic types of human papilloma virus (HPV) have been shown to be the principle cause of both cervical and anal cancer. HPV is the most common sexually transmitted disease in the United States and anal intercourse is a major risk factor for acquiring the infection. Anal cancer affects both men and women; women having the highest overall likelihood of developing carcinomas of the anorectal region. At risk populations for developing anal carcinoma include men who have sex with men, HIV positive individuals (including those without a history of anal intercourse), immunocompromised patients including a history of organ transplant, those with a history of genital warts, and women with abnormal vulvar, vaginal or cervical Pap results.
Spectrum Health Advanced Technology Laboratories are proud to announce that the first and only FDA-approved blood test for colorectal cancer screening is now available at Spectrum Health Molecular Diagnostics Laboratory. The Epi proColon Septin 9 Methylation Analysis test is indicated to screen adults of either sex, 50 years or older, defined as average risk for colorectal cancer (CRC), who have been offered and have a history of not completing CRC screening.
Beginning February 21st 2017, Spectrum Health Regional Laboratory is proud to announce that Cardiolipin IgG/IgM antibody testing will now be performed in-house as discriminatory testing. The tests can be ordered separately or in combination (see New Test Information below).
Pathologist review of peripheral blood smear (#8367) will have an additional required field to complete upon ordering. We are striving to improve our test utilization, inter-provider communication, and accurate and timely result reporting. Providers will see a choice of the top 10 to 15 reasons for review, including such reasons as “anemia evaluation” and “look for blasts”. An option for “other, see comment” is available for any free text comments to the pathologist.
This change is anticipated to begin for all electronic ordering of this test on February 4, 2016
Any questions concerning these changes may be directed to Dr. Jennifer Stumph, Director of Hematology.
As of 1/1/2017, the Flow Cytometry Laboratory at Spectrum Health Advanced Technology Laboratories will no longer accept specimens on hold. The orderable “Cell Hold by Flow Cytometry“ has been queued for inactivation. If a sample is received on hold after 1/1/2017, the ordering provider will be contacted for clarification, and appropriate testing will be performed based on the type of sample received.
Spectrum Health Regional Laboratory (SHRL) was featured on Medical Moment on Fox 17 News, Monday, September 19, 2016. Watch the clip below to go behind the scenes of our Advanced Technology Laboratories with Kim Collison, Director of Laboratory Services. Learn how ATL provides rapid turn-around of unique testing performed right here in West Michigan, which supports many key services such as oncology.
For more information on the testing that SHRL and ATL offer, please visit our Laboratory Catalog.
Spectrum Health Regional Laboratory (SHRL) was featured on EightWest on WOOD TV8 on Tuesday, August 30, 2016. Dr. Stephanie F. Williams, Division Chief of Spectrum Health Adult Bone and Marrow Transplant, and Kim Collison, Director of Laboratory Services, talk about the importance and benefits of having SHRL’s Advanced Technology Laboratory right here in West Michigan.
The Advanced Technology Laboratory is “extremely important, particularly for patients with certain cancers…”
“It helps us to diagnose the patients faster and more accurately; to follow the progress of their disease during the treatments that we give, and even at times to guide us in what is the best treatment for a patient…”
“Within 2 hours we had the answer. We did not have to send that specimen out to another laboratory in another state.”
-Stephanie F. Williams, MD, Division Chief, Spectrum Health Adult Bone and Marrow Transplant